The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant ...

The 'PROMISE 2' study included 1,072 patients who were randomized to receive eptinezumab (300mg or 100mg), or placebo once every 12 weeks. Eptinezumab (Alder BioPharmaceuticals), an investigational ...

H. Lundbeck A/S (Lundbeck) today announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted marketing authorization for eptinezumab for use in adults with migraine.

During a migraine attack, the monoclonal antibody eptinezumab (Lundbeck) provides freedom from headache pain in as little as 1 hour after intravenous (IV) administration, new research shows. New ...

Please provide your email address to receive an email when new articles are posted on . For adults with migraine and repeated preventive treatment failures, eptinezumab produced significant reductive ...

LOS ANGELES -- Eptinezumab, an intravenous calcitonin gene-related peptide (CGRP) inhibitor, met its primary endpoint in the phase III PROMISE 2 trial of chronic migraine prevention, reported ...

Lundbeck’s humanised monoclonal antibody, Vyepti (eptinezumab), has met both primary and secondary endpoints in the placebo-controlled, randomised Phase IV RESOLUTION trial in patients with chronic ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Patients who received eptinezumab, a monoclonal antibody that inhibits calcitonin gene-related ...

Lundbeck has presented new clinical data on eptinezumab at the 2025 International Headache Congress in São Paulo, highlighting its long-term preventive effectiveness in patients severely affected by ...

H LUNDBECK A/S ((HLUYY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

Alder BioPharmaceuticals has submitted a Biologics License Application to the Food and Drug Administration (FDA) for eptinezumab, an investigational monoclonal antibody (mAB) for migraine prevention.

LOS ANGELES — A single dose of the novel monoclonal antibody eptinezumab (Alder Pharmaceuticals), which targets calcitonin gene-related peptide (CGRP), is effective in the prevention of chronic ...